Sugi Predict

Sugi Predict / Compounds / SCHEMBL3399371

SCHEMBL3399371

SCHEMBL3399371

CC(=O)Oc1cc(C=O)ccc1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.66
▸ HPGD P15428 2/20 0.66
▸ TDP1 Q9NUW8 2/20 0.66
▸ TRIM24 O15164 1/20 0.66
▸ ALDH5A1 P51649 1/20 0.66
▸ ABAT P80404 1/20 0.66
▸ TRIM33 Q9UPN9 1/20 0.66
▸ KDM4E B2RXH2 3/20 0.52
▸ PTGS2 P35354 2/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ AOX1 Q06278 1/20 0.51
▸ APP P05067 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ TSHR P16473 3/20 0.47
▸ NFKB1 P19838 3/20 0.46
▸ JUN P05412 2/20 0.46
▸ CYP2D6 P10635 3/20 0.46
▸ CYP1A2 P05177 2/20 0.46
▸ ALOX5 P09917 2/20 0.46
▸ HSD11B1 P28845 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17025841 0.86 ALDH1A1 (0.66) ALDH1A1HPGDTDP1TRIM24ALDH5A1
SCHEMBL31190039 0.85 JUN (0.57) ALDH1A1HPGDTDP1TRIM24ALDH5A1
SCHEMBL320559 0.85 JUN (0.57) ALDH1A1HPGDTDP1TRIM24ALDH5A1
SCHEMBL685902 0.84 TRPA1 (0.64) ALDH1A1HPGDTDP1TRIM24ALDH5A1
SCHEMBL18196667 0.83 ALDH1A1 (0.67) ALDH1A1HPGDTDP1TRIM24ALDH5A1
SCHEMBL18130051 0.83 IAPP (0.57) ALDH1A1HPGDTDP1KDM4ERAB9A
SCHEMBL30940354 0.83 IAPP (0.57) ALDH1A1HPGDTDP1KDM4ERAB9A
SCHEMBL18130050 0.83 IAPP (0.57) ALDH1A1HPGDTDP1KDM4ERAB9A
Vanillin SCHEMBL27220604 0.82 ALDH1A1 (0.89) ALDH1A1HPGDTDP1TRIM24ALDH5A1
SCHEMBL16320920 0.82 ACHE (0.56) ALDH1A1HPGDTDP1TRIM24ALDH5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145634-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-05-08 — — US disclosed
CN-115215808-B Compositions and methods for treating cancer 加利福尼亚大学董事会 2025-04-18 — — CN disclosed
US-20240058340-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER ERASCA, INC. 2024-02-22 — — US disclosed
US-20230364091-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-11-16 — — US disclosed
US-20230364091-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-11-16 — — US disclosed
US-20230364091-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-11-16 — — US disclosed
US-20230115366-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-04-13 — — US disclosed
CN-115215808-A Compositions and methods for treating cancer 加利福尼亚大学董事会 2022-10-21 — — CN disclosed
US-11377451-B2 Compositions and methods for treating cancer THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-07-05 — — US disclosed
US-11377451-B2 Compositions and methods for treating cancer THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-07-05 — — US disclosed
US-20130109710-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2013-05-02 — — US disclosed
US-8299296-B2 Spiro compounds and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2012-10-30 — — US disclosed
US-8299296-B2 Spiro compounds and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2012-10-30 — — US disclosed
US-8299296-B2 Spiro compounds and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2012-10-30 — — US disclosed
EP-2508503-A1 Spiro compounds and pharmaceutical use thereof Japan Tobacco, Inc. (JP) 2012-10-10 — — EP disclosed
EP-2202216-B1 SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES JAPAN TOBACCO INC (JP) 2012-06-27 — — EP disclosed
EP-2202216-A1 SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES Japan Tobacco Inc. (JP) 2010-06-30 — — EP disclosed
US-20090170908-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2009-07-02 — — US disclosed
US-20090170908-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2009-07-02 — — US disclosed
US-20090170908-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170908-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF REN, PKD1, PKD2 ALDH1A1 268/4885HPGD 374/4885TDP1 4593/4885
US-20250145634-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER TP53, SLC2A1, EGFR ALDH1A1 2784/4885HPGD 1757/4885TDP1 492/4885
US-11377451-B2 Compositions and methods for treating cancer TP53, EGFR, SLC2A1 ALDH1A1 2649/4885HPGD 1829/4885TDP1 504/4885
US-20130109710-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF REN, PKD1, PKD2 ALDH1A1 268/4885HPGD 374/4885TDP1 4593/4885
US-20230115366-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER TP53, SLC2A1, EGFR ALDH1A1 2784/4885HPGD 1757/4885TDP1 492/4885
US-20230364091-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER TP53, EGFR, SLC2A1 ALDH1A1 2584/4885HPGD 1603/4885TDP1 490/4885
US-20240058340-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER TP53, EGFR, SLC2A1 ALDH1A1 2584/4885HPGD 1603/4885TDP1 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.